Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

688505 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Trading 12-15 09:53:46

8.40

-0.02

-0.24%

High8.41	Low8.28	Vol820.24K
Open8.38	D1 Closing8.42	Amplitude1.54%
Mkt Cap8.71B	Tradable Cap5.97B	Total Shares1.04B
T/O6.84M	T/O Rate0.12%	Tradable Shares711.00M
P/B3.86	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"688505","market":"SH","secType":"STK","nameCN":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.","latestPrice":8.4,"timestamp":1765763626000,"preClose":8.42,"halted":0,"volume":820238,"delay":0,"changeRate":-0.0024,"floatShares":711000000,"shares":1036999999,"eps":-0.0605,"marketStatus":"Trading","change":-0.02,"latestTime":"12-15 09:53:46","open":8.38,"high":8.41,"low":8.28,"amount":6835500,"amplitude":0.0154,"askPrice":8.4,"askSize":332,"bidPrice":8.38,"bidSize":53,"shortable":0,"etf":0,"ttmEps":-0.0605,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1765769400000},"marketStatusCode":2,"adr":0,"adjPreClose":8.42,"symbolType":"stock_kcb","openAndCloseTimeList":[[1765762200000,1765769400000],[1765774800000,1765782000000]],"highLimit":9.26,"lowLimit":7.58,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1036572100,"isCdr":false,"pbRate":3.86,"roa":"--","roe":"--","epsLYR":0.04,"committee":-0.411295,"marketValue":8707000000,"turnoverRate":0.0012,"status":1,"hkstockBrief":{"symbol":"01349","market":"HK","secType":"STK","nameCN":"FUDANZHANGJIANG","latestPrice":2.89,"timestamp":1765763613327,"preClose":2.89,"halted":0,"volume":189000,"delay":0,"premium":"-68.83"},"floatMarketCap":5969000000},"requestUrl":"/m/hq/s/688505/tweets","defaultTab":"tweets","newsList":[{"id":"1101578416","title":"FUDANZHANGJIANG (01349): Qu Yanan Elected as Employee Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1101578416","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101578416?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:16","pubTimestamp":1764159374,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced that the company held the third session of the third Employee Representatives Congress on November 26, 2025, reviewing and approving the proposal regarding the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0239","688505","01349"],"gpt_icon":0},{"id":"2586251689","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Files Director List to HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2586251689","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586251689?lang=en_us&edition=fundamental","pubTime":"2025-11-26 20:00","pubTimestamp":1764158400,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has filed an updated list of directors and their respective roles with the Hong Kong Stock Exchange. The company's eighth board of directors comprises Zhao Da Jun , Xue Yan , Shen Bo and Yu Xiao Yang , Wang Hong Guang, Lam Siu Wing, and Xu Pei Long , and Qu Ya Nan . Committee memberships are as follows: Zhao Da Jun serves as Chairman of the Strategy Committee; Xue Yan is a member of the Nomination Committee; Shen Bo is a member of the Audit Committee; Wang Hong Guang is Chairman of the Remuneration Committee and a member of both the Strategy and Audit Committees; Lam Siu Wing is Chairman of the Audit Committee and a member of both the Remuneration and Nomination Committees; Xu Pei Long is Chairman of the Nomination Committee and a member of the Strategy and Remuneration Committees.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4mcXNr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2586052259","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. held extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586052259","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586052259?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:58","pubTimestamp":1764158291,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. held an extraordinary general meeting on November 26, 2025. All proposals put forward at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4NdrTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"1157948437","title":"FUDANZHANGJIANG (01349) Shareholder Yang Zongmeng Plans to Sell Up to Approximately 10.37 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1157948437","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157948437?lang=en_us&edition=fundamental","pubTime":"2025-11-04 18:26","pubTimestamp":1762251976,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced that the company recently received a notice from shareholder Mr. Yang Zongmeng regarding his plan to reduce his shareholding. Due to personal financial needs, Mr....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01349","BK1191","688505","BK0239"],"gpt_icon":0},{"id":"2579467469","title":"Shareholders to Vote on Change in Use of IPO Proceeds at Next Shanghai Fudan-Zhangjiang Bio-Pharmaceutical EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2579467469","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579467469?lang=en_us&edition=fundamental","pubTime":"2025-10-31 21:31","pubTimestamp":1761917471,"startTime":"0","endTime":"0","summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. will hold an extraordinary general meeting on a future date to vote on a proposal to change the use of proceeds from its A share initial public offering. The proposal seeks shareholder approval to reallocate unused funds from the original project to a new project, with an adjusted utilisation timeline extending to 31 December 2027. The board recommends voting in favor of the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDL6cZ36f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505"],"gpt_icon":0},{"id":"1110255030","title":"FUDANZHANGJIANG (01349) Reports Net Loss of RMB15.94 Million for First Three Quarters, Shifting from Profit to Loss YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=1110255030","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110255030?lang=en_us&edition=fundamental","pubTime":"2025-10-30 18:48","pubTimestamp":1761821292,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced its financial results for the nine months ended September 30, 2025. The group recorded revenue of RMB551 million, a year-on-year increase of 0.41%. However, it...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK1191","01349","BK0239"],"gpt_icon":0},{"id":"1192564828","title":"Fudan Zhangjiang's Obeticholic Acid Generic Drug Fails, 125 Million R&D Investment Wasted: What Risks Are Hidden Behind?","url":"https://stock-news.laohu8.com/highlight/detail?id=1192564828","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192564828?lang=en_us&edition=fundamental","pubTime":"2025-10-17 14:40","pubTimestamp":1760683258,"startTime":"0","endTime":"0","summary":"Recently, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as \"Fudan Zhangjiang\") announced that its wholly-owned subsidiary, Taizhou Fudan Zhangjiang, has not received...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","01349","BK1191","BK0239"],"gpt_icon":0},{"id":"1144574346","title":"Fudan Zhangjiang (01349) Invests RMB 100 Million in Structured Deposit Product from China Merchants Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=1144574346","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144574346?lang=en_us&edition=fundamental","pubTime":"2025-10-15 17:26","pubTimestamp":1760520380,"startTime":"0","endTime":"0","summary":"Fudan Zhangjiang (01349) announced that it has entered into a structured deposit product agreement I with China Merchants Bank (CM BANK). Additionally, its wholly-owned subsidiary Taizhou Fudan...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348814723.USD","LU0117841782.USD","LU0326950275.SGD","BK0278","LU0516422440.USD","LU0348827113.USD","LU1146622755.USD","LU0463099449.HKD","LU1820825898.SGD","LU2097828631.EUR","LU0384037296.USD","BK0012","01349","BK0239","LU1813983027.USD","LU1023057109.AUD","LU0011963245.USD","BK1507","LU0469268626.HKD","SG9999001903.USD","LU0051755006.USD","LU2580892789.USD","LU2476274308.USD","LU0516422366.SGD","LU0880133367.SGD","LU0634319403.HKD","LU0231483743.USD","LU1282648689.USD","LU0417516738.SGD","LU0588546209.SGD","BK1231","LU0823426308.USD","SGXZ81163826.USD","LU1366334651.USD","LU0210526637.USD","LU0821914370.USD","LU1880383440.USD","LU0140636845.USD","LU1255011170.USD","LU0327786744.USD","LU0320764243.SGD","LU1808992512.USD","LU0593848301.USD","LU0868486357.SGD","LU0287142896.SGD","LU1282649141.HKD","LU2097828805.USD","LU1211504680.USD","LU0516422952.EUR","SG9999000459.SGD","BK0183","LU1251922891.USD","IE00B3M56506.USD","LU0979878070.USD","LU1720050803.USD","LU1242518857.USD","688505","LU1997245177.USD","LU1152091168.USD","LU1655091616.SGD","LU1675838814.USD","IE0031814852.USD","IE0008369823.USD","LU1282649067.USD","LU1064130708.USD","IE00B031J352.USD","IE00BVYPNQ40.USD","IE00B543WZ88.USD","LU0708995583.HKD","LU0307460666.USD","LU0244354667.USD","LU0359202008.SGD","LU0589944569.HKD","LU1064131003.USD","BK0015","LU0456846285.SGD","LU2580892862.HKD","LU0890818403.SGD","LU1188198961.HKD","LU2039709279.SGD","BK1521","LU1282649810.SGD","LU0417516902.SGD","03143","LU0228367735.SGD","LU1770034418.SGD","LU1997245094.SGD","IE00BMCWC346.EUR","LU0516423174.USD","LU0314109678.HKD","IE00BZ08YT58.USD","LU1960683339.HKD","LU2097828557.USD","IE00BZ08YR35.GBP","LU1794554557.SGD","LU1115378108.SGD","SGXZ49509284.SGD","LU1152091754.HKD","LU1831875114.USD","LU1242518931.SGD","LU1993786604.SGD","LU1997244956.HKD","LU2097828474.EUR","LU1226287529.USD","LU2097828714.EUR","SG9999002828.SGD","LU0456827905.SGD","BK0187","IE00BGHQDM52.EUR","IE00BYV24P56.USD","LU0348816934.USD","LU0640798160.USD","LU0348805143.USD","LU1688375341.USD","LU0488056044.USD","LU2226246903.HKD","LU0320764599.SGD","IE00BF5LJ272.USD","IE00B29SXG58.USD","LU0918141705.HKD","BK0028","SG9999002463.SGD","LU2476274720.SGD","LU1969619763.USD","BK1560","LU0823426480.USD","LU0348735423.USD","LU0359201612.USD","LU0348788117.USD","IE00B5MMRT66.SGD","03968","BK0188","LU0348825331.USD","LU1580142542.USD","LU2242644610.SGD","LU0173614495.USD","LU1979443071.USD","LU0862451753.SGD","LU1781817850.SGD","LU0431992006.USD","LU2148510915.USD","LU0315179316.USD","BK0010","LU0791591158.USD","LU0072913022.USD","BK0070","LU1807302812.USD","IE0008368742.USD","LU0543330566.HKD","LU0029874905.USD","LU2328871848.SGD","LU1105468828.SGD","LU1934453819.USD","LU0540923850.HKD","LU0229945570.USD","LU0561508036.HKD","LU1719994722.HKD","LU0501845795.SGD","LU0737861699.HKD","LU1328277881.USD","LU1880383366.USD","LU0648948544.HKD","LU0048580855.USD","BK1610","LU0370786039.SGD","LU0106959298.USD","LU0516423091.SGD","BK1191","LU0791590937.USD","LU0797268264.HKD","LU0918141887.USD","LU1366334578.USD","IE00BVYPNP33.GBP","LU2289578879.USD","LU2399975544.HKD","600036","LU0052750758.USD","LU1008478684.HKD","LU0455707207.USD","IE00BZ08YS42.EUR","LU2213484517.USD","LU1224709979.USD","LU0708995153.HKD","LU0047713382.USD","LU0502904849.HKD","SG9999004220.SGD","LU0067412154.USD","LU2778985437.USD","LU1961090484.USD","LU0128522744.USD","LU1303224171.USD","LU0163747925.USD","LU2495084118.USD","LU1048596156.SGD","LU0572944931.SGD","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2575820733","title":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Says Group Agreed To Subscribe For Structured Deposit Products For RMB100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2575820733","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575820733?lang=en_us&edition=fundamental","pubTime":"2025-10-15 17:23","pubTimestamp":1760520194,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Says Group Agreed To Subscribe For Structured Deposit Products For RMB100 MillionOct 15  - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 688505.SS:GROUP AGREED TO SUBSCRIBE FOR STRUCTURED DEPOSIT PRODUCTS FOR RMB100 MILLIONFurther company coverage: 688505.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VV27T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2575207868","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Group Agreed to Subscribe for Structured Deposit Products for RMB100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2575207868","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575207868?lang=en_us&edition=fundamental","pubTime":"2025-10-15 17:22","pubTimestamp":1760520149,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nFWN3VV27T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"1180995695","title":"FUDANZHANGJIANG (01349) Subscribes to RMB 170 Million Structured Deposit Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1180995695","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180995695?lang=en_us&edition=fundamental","pubTime":"2025-10-14 16:58","pubTimestamp":1760432303,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced that the company recently entered into China Bank Structured Deposit Product Agreement I and China Bank Structured Deposit Product Agreement II with Bank of China....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01349","688505","BK0239","BK1191"],"gpt_icon":0},{"id":"2575267666","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical-  to Subscribe for Structured Deposit Products With Total Amount of RMB170 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2575267666","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575267666?lang=en_us&edition=fundamental","pubTime":"2025-10-14 16:54","pubTimestamp":1760432080,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV1E2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"1192988162","title":"Listed Company's 125 Million Yuan Generic Drug Application Rejected as Original Drug \"Crashes\": Withdrawn from European and US Markets Due to Safety Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=1192988162","media":"Deep News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192988162?lang=en_us&edition=fundamental","pubTime":"2025-10-14 13:41","pubTimestamp":1760420471,"startTime":"0","endTime":"0","summary":"Listed Company's 125 Million Yuan Generic Drug Application Rejected as Original Drug \"Crashes\": Withdrawn from European and US Markets Due to Safety Issues, All Related Clinical Trials Suspended On...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","FXR","EMA","EC","BK4201","PBC","688505","BK4081"],"gpt_icon":0},{"id":"2575288016","title":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Says Obeticholic Acid Tablets Drug Application Not Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2575288016","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575288016?lang=en_us&edition=fundamental","pubTime":"2025-10-13 23:31","pubTimestamp":1760369461,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Says Obeticholic Acid Tablets Drug Application Not ApprovedOct 13 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 688505.SS:NEW DRUG ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VR2XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2575403559","title":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes Structured Deposit Product Under Ping An Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2575403559","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575403559?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:33","pubTimestamp":1760355189,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Subscribes Structured Deposit Product Under Ping An BankOct 13 (Reuters) - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 688505.SS:SUBSCRIPTION","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688505","BK0239"],"gpt_icon":0},{"id":"1127365595","title":"FUDANZHANGJIANG (01349): Marketing Application for Obeticholic Acid Tablets for Primary Biliary Cholangitis Treatment Rejected","url":"https://stock-news.laohu8.com/highlight/detail?id=1127365595","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127365595?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:08","pubTimestamp":1760350099,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced that its subsidiary Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd. has received a \"Drug Marketing Application Disapproval Notice\" issued by the National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688505","01349","BK1191"],"gpt_icon":0},{"id":"2575836472","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - Notification Received From National Medical Products Administration of PRC","url":"https://stock-news.laohu8.com/highlight/detail?id=2575836472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575836472?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:02","pubTimestamp":1760349740,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VR2XC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["688505","BK0239"],"gpt_icon":0},{"id":"2575472834","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical - New Drug Application for Obeticholic Acid Tablets Was Not Approved","url":"https://stock-news.laohu8.com/highlight/detail?id=2575472834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575472834?lang=en_us&edition=fundamental","pubTime":"2025-10-13 18:02","pubTimestamp":1760349740,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VR2XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"2575448471","title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Subscription of Structured Deposit Product Under Ping an Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2575448471","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575448471?lang=en_us&edition=fundamental","pubTime":"2025-10-13 17:36","pubTimestamp":1760348213,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nFWN3VT01F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688505"],"gpt_icon":0},{"id":"1143916591","title":"FUDANZHANGJIANG Subscribes to 210 Million Yuan Structured Deposit Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1143916591","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143916591?lang=en_us&edition=fundamental","pubTime":"2025-10-13 09:00","pubTimestamp":1760317254,"startTime":"0","endTime":"0","summary":"FUDANZHANGJIANG (01349) announced that the company has recently entered into a structured deposit product agreement with Shanghai Pudong Development Bank. The company has agreed to subscribe to structured deposit products totaling RMB 210 million using idle funds generated from daily operations.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01349","688505","BK1191","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-06-19","address":"上海市浦东新区张江高科技园区蔡伦路308号","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.0706},{"period":"3month","weight":-0.1275},{"period":"6month","weight":-0.0181},{"period":"1year","weight":-0.0238},{"period":"ytd","weight":0.1009}],"companyName":"上海复旦张江生物医药股份有限公司","boardCode":"AI0027","perCapita":"33828股","boardName":"医药制造业","registeredCapital":"10365万元","compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0277},{"period":"3month","weight":0.0048},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1236},{"period":"ytd","weight":0.1604}],"survey":"　　上海复旦张江生物医药股份有限公司的主营业务是生物医药的创新研究开发、生产制造和市场营销。公司的主要产品是皮肤科产品、抗肿瘤产品。","serverTime":1765763631948,"listedPrice":8.95,"stockholders":"21005人(较上一季度增加6.42%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.,688505,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票老虎,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票老虎国际,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.行情,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票行情,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股价,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股市,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票价格,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票交易,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票购买,Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.(688505) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}